Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
AxoGen (DE:LT3)
FRANKFURT:LT3
Holding DE:LT3?
Track your performance easily
LT3 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€5.10 - €14.30
Previous Close€14.2
Volume0.00
Average Volume (3M)N/A
Market Cap
€626.56M
Enterprise Value€681.55M
Total Cash (Recent Filing)$24.53M
Total Debt (Recent Filing)$47.27M
Price to Earnings (P/E)―
Beta1.06
Next Earnings
Mar 04, 2025EPS Estimate
€0.03Last Dividend Ex-Date
Jan 27, 2010Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding44,008,259
10 Day Avg. Volume0
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)6.28
Price to Sales (P/S)3.81
Price to Cash Flow (P/CF)44.10
P/FCF Ratio62.30
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.77
Enterprise Value/Gross Profit5.33
Enterprise Value/Ebitda-402.33
Forecast
1Y Price Target
€17.69Price Target Upside24.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
AxoGen News
PremiumCompany Announcements
Axogen Reports Strong Q3 Growth and FDA Progress
PremiumCompany Announcements
AxoGen Reports Strong Q3 2024 Revenue Growth
Bulls Say, Bears Say
Bulls Say
Financial PerformanceAXGN posted solid Q3 results, beating top- and bottom-line expectations.
Market ExpansionAxoGen has truly differentiated products for nerve protection and repair, facing limited biologic competition, which presents ample growth opportunities.
Product ApprovalFDA approval of Avance in 2025 is considered less risky after the agency accepted the BLA submission.
Bears Say
Management GuidanceThe management's reiteration of full-year guidance was seen as overly conservative, contributing to an unwarranted sell-off.
Regulatory ChallengesThe FDA did not grant AXGN's request for priority review, resulting in a later decision date.
Stock PerformanceAXGN shares fell significantly, attributed to maintaining FY24 revenue guidance despite a topline beat.
---
Options Prices
Currently, No data available
---
Ownership Overview
5.41% Insiders
18.34% Mutual Funds
39.08% Other Institutional Investors
23.11% Public Companies and
Individual Investors
LT3 FAQ
What was AxoGen’s price range in the past 12 months?
AxoGen lowest stock price was €5.10 and its highest was €14.30 in the past 12 months.
What is AxoGen’s market cap?
Currently, no data Available
When is AxoGen’s upcoming earnings report date?
AxoGen’s upcoming earnings report date is Mar 04, 2025 which is in 72 days.
How were AxoGen’s earnings last quarter?
AxoGen released its earnings results on Nov 07, 2024. The company reported €0.067 earnings per share for the quarter, beating the consensus estimate of €0.006 by €0.061.
Is AxoGen overvalued?
According to Wall Street analysts AxoGen’s price is currently Undervalued.
Does AxoGen pay dividends?
AxoGen pays a Notavailable dividend of €0.952 which represents an annual dividend yield of N/A. See more information on AxoGen dividends here
What is AxoGen’s EPS estimate?
AxoGen’s EPS estimate is €0.03.
How many shares outstanding does AxoGen have?
AxoGen has 44,008,260 shares outstanding.
What happened to AxoGen’s price movement after its last earnings report?
AxoGen reported an EPS of €0.067 in its last earnings report, beating expectations of €0.006. Following the earnings report the stock price went down -1.399%.
Which hedge fund is a major shareholder of AxoGen?
Among the largest hedge funds holding AxoGen’s share is Driehaus Capital Management LLC. It holds AxoGen’s shares valued at 5M.
---
AxoGen Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€17.69 (24.55% Upside)
€17.69 (24.55% Upside)
Blogger Sentiment
Bullish
DE:LT3 Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
125.03%
12-Months-Change
Fundamentals
Return on Equity
-14.51%
Trailing 12-Months
Asset Growth
-1.36%
Trailing 12-Months
Company Description
AxoGen
AxoGen, Inc. engages in the development and market of surgical solutions for peripheral nerves. It also provides products and education to improve surgical treatment algorithms for peripheral nerve damage or discontinuity. Its products include avance nerve graft, axoguard nerve connector, axoguard nerve protector, avive soft tissue membrane, acroval neurosensory and motor testing system, and axotouch two-point discriminator. The company was founded in 1977 and is headquartered in Alachua, FL.
---
LT3 Company Deck
---
LT3 Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a positive outlook with strong revenue growth and strategic advancements, particularly with the BLA submission and FDA acceptance. However, challenges remain with a decrease in gross margin and continued net losses.Read More>---
LT3 Stock 12 Month Forecast
Average Price Target
€17.69
▲(24.55% Upside)
Technical Analysis
AxoGen
―
TransMedics Group
―
Fate Therapeutics
―
Axsome Therapeutics
―
Kala Pharmaceuticals
―
Best Analysts Covering LT3
1 Year
1 Year Success Rate
12/23 ratings generated profit
1 Year Average Return
+28.00%
reiterated a buy rating last month
Copying David Turkaly's trades and holding each position for 1 Year would result in 52.17% of your transactions generating a profit, with an average return of +28.00% per trade.
---